Radioimmunotherapy for lymphoma Journal Article


Author: Zelenetz, A. D.
Article Title: Radioimmunotherapy for lymphoma
Abstract: After more than a decade of unfulfilled promises, radioimmunotherapy for the treatment of non-Hodgkin's lymphoma has been demonstrated to be efficacious in the treatment of refractory disease. It is likely that in the near future, the Food and Drug Administration will approve one or more radioimmunoconjugates for clinical use. However, the optimal use of the agents in the treatment of non-Hodgkin's lymphoma remains to be defined. The role for these drugs is influenced by the target antigen as well as the radionuclide. In this review, the biologic principles, seminal clinical results, and avenues for future development of RIT are discussed.
Keywords: review; monoclonal antibody; membrane antigen; nonhodgkin lymphoma; lymphoma, non-hodgkin; lymphoma; radioisotope; radioimmunotherapy; clinical trials; immunoconjugates; humans; human; priority journal
Journal Title: Current Opinion in Oncology
Volume: 11
Issue: 5
ISSN: 1040-8746
Publisher: Lippincott Williams & Wilkins  
Date Published: 1999-09-01
Start Page: 375
End Page: 380
Language: English
DOI: 10.1097/00001622-199909000-00009
PUBMED: 10505774
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 16 August 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew D Zelenetz
    781 Zelenetz